T1	Participants 97 124	adults with type 1 diabetes
T2	Participants 209 256	intensively treated adults with type 1 diabetes
T3	Participants 297 458	83 of 86 individuals >or=25 years of age with type 1 diabetes who used CGM as part of a 6-month randomized clinical trial in a subsequent 6-month extension study
